Portal de Periódicos da CAPES

Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients

2006; Wiley; Volume: 26; Issue: 2 Linguagem: Inglês

10.1002/nau.20367

1520-6777

Martin C. Michel, Matthias Oelke, Μ. Goepel, Elmar Beck, Martin Burkart,

Urinary Tract Infections Management

Abstract Aims We have studied the association between various symptoms, bother, and patient treatment satisfaction in overactive bladder (OAB). Methods Episodes of urgency, incontinence, daytime frequency and nocturia and responses to the patient perception of bladder condition scale, the urgency perception scale, and visual analog scales of limitations in daily life and of treatment satisfaction were evaluated in 3,824 OAB patients at baseline and during 9 months treatment with tolterodine ER (4 mg q.d.) in an open‐label, observational study. Relationships amongst number of symptoms/ 24 hr and scales were explored. Treatment satisfaction was correlated with improvements in symptoms and scales. Results At baseline, the number of episodes of the four OAB symptoms correlated only poorly with each other and with the two bother‐related scales, while the two scales assessing bother correlated much stronger with each other. Factor analysis identified four components which described “bother,” “incontinence,” “urgency/frequency,” and “nocturia” and in combination explained 81.9% of the total variance. The component “bother” had the strongest individual effect accounting for 42.1% of the total variance. While improvements of symptoms and bother were seen with tolterodine treatment, patient treatment satisfaction correlated strongest with improvements of the two bother‐related scales. Conclusions We conclude that the counting of episodes of OAB symptoms only insufficiently describes the afflicted patients. Patient bother is the strongest individual component but only poorly explained by episodes of the four symptoms defining OAB. Alterations of bother may better reflect patient‐relevant outcomes in OAB treatment than alterations in the number of symptom episodes. Neurourol. Urodynam. 26:190–195, 2007. © 2006 Wiley‐Liss, Inc.